Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating tadalafil and tamsulosin versus tamsulosin alone in men with symptomatic benign prostatic hyperplasia
IRCT20251121068066N14Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in benign prostatic hyperplasia (BPH) comparing Daily tamsulosin with Alternating tadalafil and tamsulosin (2 arms). Primary endpoints: Lower urinary tract symptoms and Sexual function. Started Sep 2026; status: completed.
02
Drugs
tadalafiltamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20251121068066N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251121068066N14.